Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

Payal Kohli; Nihar R. Desai; Robert P. Giugliano; Jae B. Kim; Ransi Somaratne; Fannie Huang; Beat Knusel; Shannon McDonald; Timothy Abrahamsen; Scott M. Wasserman; Robert Scott; Marc S. Sabatine

doi:10.1002/clc.22014

Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

Clinical Cardiology ◽

10.1002/clc.22014 ◽

2012 ◽

Vol 35 (7) ◽

pp. 385-391 ◽

Cited By ~ 34

Author(s):

Payal Kohli ◽

Nihar R. Desai ◽

Robert P. Giugliano ◽

Jae B. Kim ◽

Ransi Somaratne ◽

...

Keyword(s):

Monoclonal Antibody ◽

Statin Therapy ◽

Phase Ii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.34330 ◽

2012 ◽

Vol 64 (6) ◽

pp. 1730-1739 ◽

Cited By ~ 100

Author(s):

Michael Yellin ◽

Igor Paliienko ◽

Andra Balanescu ◽

Semen Ter-Vartanian ◽

Vira Tseluyko ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase Ii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

Safety and Efficacy of Monoclonal Antibody VIS410 in Adults with Uncomplicated Influenza A Infection: Results from a Randomised, Double-Blind, Placebo-Controlled Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271424 ◽

2018 ◽

Author(s):

Ellie Hershberger ◽

Susan Sloan ◽

Kristin Narayan ◽

Catherine A. Hay ◽

Patrick Smith ◽

...

Keyword(s):

Monoclonal Antibody ◽

Influenza A ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text

Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study

Contraception ◽

10.1016/j.contraception.2018.02.014 ◽

2018 ◽

Vol 98 (1) ◽

pp. 56-62 ◽

Cited By ~ 7

Author(s):

Rik H.W. van Lunsen ◽

Yvette Zimmerman ◽

Herjan J.T. Coelingh Bennink ◽

Hanneke M.M. Termeer ◽

Nicole Appels ◽

...

Keyword(s):

Sexual Function ◽

Phase Ii ◽

Oral Contraceptives ◽

Controlled Study ◽

Double Blind ◽

Combined Oral Contraceptives ◽

Double Blind Placebo ◽

Testosterone Levels

Download Full-text

Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease

American Heart Journal ◽

10.1016/j.ahj.2007.01.038 ◽

2007 ◽

Vol 153 (5) ◽

pp. 874-880 ◽

Cited By ~ 53

Author(s):

Paul Michael Grossman ◽

Farrell Mendelsohn ◽

Timothy D. Henry ◽

James B. Hermiller ◽

Marc Litt ◽

...

Keyword(s):

Peripheral Arterial Disease ◽

Intermittent Claudication ◽

Phase Ii ◽

Arterial Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Peripheral Arterial

Download Full-text

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Investigational New Drugs ◽

10.1007/s10637-018-0630-9 ◽

2018 ◽

Vol 36 (5) ◽

pp. 919-926 ◽

Cited By ~ 1

Author(s):

Paul Monk ◽

Glenn Liu ◽

Walter M. Stadler ◽

Susan Geyer ◽

Ying Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Controlled Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant

Download Full-text

Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study

British Journal of Clinical Pharmacology ◽

10.1111/bcp.13748 ◽

2018 ◽

Vol 85 (2) ◽

pp. 304-315 ◽

Cited By ~ 13

Author(s):

Joanne Ellis ◽

Andre Maurik ◽

Lea Fortunato ◽

Sophie Gisbert ◽

Keguan Chen ◽

...

Keyword(s):

Monoclonal Antibody ◽

Healthy Subjects ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving fluropyrimidines and/or irinotecan-based therapy

Annals of Oncology ◽

10.1093/annonc/mdy424.085 ◽

2018 ◽

Vol 29 ◽

pp. viii755 ◽

Cited By ~ 2

Author(s):

A. Sharma ◽

S.P. Chaudhary ◽

V. Raina ◽

N.K. Shukla ◽

V. Sreenivas ◽

...

Keyword(s):

Cancer Patients ◽

Phase Ii ◽

Controlled Study ◽

High Potency ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Abstract 4531: SWATH-MS profiling identifies prognostic factors for progression-free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG)

10.1158/1538-7445.sabcs18-4531 ◽

2019 ◽

Author(s):

Sarah A. Hayes ◽

Andrew Martin ◽

Sonia Yip ◽

Viive M. Howell ◽

Katrin M. Sjoquist ◽

...

Keyword(s):

Prognostic Factors ◽

Phase Ii ◽

Progression Free Survival ◽

Controlled Study ◽

Double Blind ◽

Free Survival ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

Oesophagogastric Cancer

Download Full-text